(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/222552 A1

(51) International Patent Classification:
*A61K 31/454* (2006.01) *A61K 45/06* (2006.01)
*A61K 31/4545* (2006.01) *A61P 35/02* (2006.01)
*A61K 31/496* (2006.01) *A61P 37/02* (2006.01)
*A61K 31/517* (2006.01) *C07K 16/28* (2006.01)
*A61K 31/5377* (2006.01)

(21) International Application Number:
PCT/US2021/029877

(22) International Filing Date:
29 April 2021 (29.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20172322.8 30 April 2020 (30.04.2020) EP

(71) Applicant: **CELGENE CORPORATION** [US/US]; 86 Morris Avenue, Summit, New Jersey 07901 (US).

(72) Inventors; and
(71) Applicants: **JEYARAJU, Danny Vijey** [CA/US]; c/o Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901 (US). **AMATANGELO, Michael** [US/US]; c/o Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901 (US). **LA MOTTE-MOHS, Ross** [US/US]; c/o Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901 (US). **PIERCEALL, William** [US/US]; c/o Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901 (US). **THAKURTA, Anjan G.** [US/US]; c/o Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** METHODS OF TREATING CYTOKINE-RELATED ADVERSE EVENTS

Fig. 11




(57) **Abstract:** The disclosure relates to agents for use in the treatment or prevention of a cytokine-related adverse event or disease, such as cytokine release syndrome (CRS).

WO 2021/222552 A1